pharmaphorum

JULY 14, 2022

The legacy product now lies outside Bayer’s core areas of cardiology, oncology, haematology, ophthalmology, women’s health and radiopharmaceuticals, and the funds raised from the sale will support the “ongoing transformation of Bayer’s pharma business to focus on key areas of future medical innovation”, said the company.

Drugs 97

Drugs Sales Pharma Companies Cardiology 97

pharmaphorum

JANUARY 7, 2022

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery. Shortly after Amgen unveiled its $1.9 Shortly after Amgen unveiled its $1.9

Drugs 111

Drugs Pharma Companies Medicine Licensing 111

pharmaphorum

FEBRUARY 13, 2022

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

XTalks

AUGUST 21, 2023

The US Food and Drug Administration (FDA) has approved Ipsen’s groundbreaking Sohonos (palovarotene) capsules for the treatment of fibrodysplasia ossificans progressive (FOP), an ultra-rare bone disease. Sohonos, the first and only approved drug, offers hope to those battling the disease.

Drugs 98

Drugs FDA Approval Genetics Clinical Trials 98

Drug Discovery World

FEBRUARY 5, 2024

One-third (32%) of rare disease patients are not aware they can access unlicensed medicines through Early Access Programmes, new research has revealed. However, two-thirds (68%) of patients are comfortable receiving medicines before they’re licensed through their country’s healthcare system.

Medicine 52

Medicine Pharma Companies Licensing Licensing 52

pharmaphorum

FEBRUARY 12, 2021

Along with the $350 million upfront fee Sandoz is also pledging $150 million tied to sales performance in the deal, which excludes some rights to the drug in some markets including the US, China, Germany and Australia. The post Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs appeared first on.

Drugs 111

Drugs Sales Pharma Companies Marketing 111

pharmaphorum

FEBRUARY 3, 2022

India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum. The two drugs were developed by medical cannabis pioneer GW Pharma, which was acquired by Jazz last year.

Licensing 120

Licensing Licensing Marketing Sales 120

pharmaphorum

MAY 13, 2022

Bristol-Myers Squibb’s flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy Opdivo. The post BMS doubles down on BridgeBio alliance on SHP2 drugs appeared first on.

Drugs 59

Drugs Pharma Companies Licensing Licensing 59

pharmaphorum

FEBRUARY 11, 2022

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. billion takeover of Clementia Pharma in 2019. billion takeover of Clementia Pharma in 2019. billion of its revenues last year. billion of its revenues last year.

Sales 104

Sales Pharma Companies Branding Cosmetics 104

Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely.

Development 242

Development Bioequivalency Generic Drugs Production 242

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

pharmaphorum

JANUARY 24, 2023

Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the field of inflammatory bowel disease (IBD). Symptoms include diarrhoea, abdominal pain and cramping, tiredness, and weight loss.

Medicine 52

Medicine Drugs Pharma Companies Licensing 52

pharmaphorum

OCTOBER 28, 2020

Claus Møldrup explores research showing that patients want their voice to be heard more by pharma, and asks what a truly effective feedback loop for medicines might look like. Pharma remains stubbornly closed to feedback, with potentially damaging consequences for the industry, healthcare systems and patients.

Medicine 120

Medicine Pharma Companies Vaccination Vaccine 120

pharmaphorum

JANUARY 8, 2021

There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. It is already in the late stages of development and expected to be approved in Europe later this year.

Licensing 52

Licensing Licensing Pharma Companies Branding 52

pharmaphorum

JUNE 4, 2021

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo – continue to decline. . The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 82

Antibody Licensing Licensing Sales 82

pharmaphorum

APRIL 22, 2021

In a filing with the Securities and Exchange Commission, Centessa said it plans to use proceeds to fund the development of the 16 drugs in its pipeline, as well as potential acquisitions. The company has an “asset focused” R&D philosophy , where development is centred on the needs of each individual biotech.

Licensing 65

Licensing Licensing Pharma Companies Drugs 65

Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. However, to invest in drug development for this condition, a number of methodological issues will need to be addressed.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

Camargo

SEPTEMBER 23, 2020

Panel Summary from the World Orphan Drug Congress 2020. Last month, executives from leading international biopharma companies came together at the World Orphan Drug Congress 2020 to discuss how they are evaluating new opportunities in the rare disease space. Thomas Kassberg, Chief Business Officer, Ultragenyx.

Business Development 136

Business Development Drugs Development Production 136

pharmaphorum

FEBRUARY 15, 2022

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 Lilly is thought to be the first pharma company to sign up to use the new camptothecin payload platform. million payment to the biotech.

Antibody 52

Antibody Licensing Licensing Drugs 52

pharmaphorum

DECEMBER 9, 2022

Sanofi has walked away from a four-year-old partnership with Revolution Medicines focused on an SHP2 inhibitor, intended as a combination with KRAS inhibitors, including Sanofi’s Mirati-partnered adagrasib. Sanofi did not give much away about the reasons for its decision, other than to point to shifting priorities in its R&D portfolio.

Pharma Companies 59

Pharma Companies Licensing Licensing Trials 59

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

pharmaphorum

OCTOBER 7, 2021

The factory will be able to supply up to 500 million doses of mRNA shots a year, and cover the full spectrum of manufacturing from drug substance production through to full/finish and packaging, according to the company.

Vaccination 98

Vaccination Vaccine Manufacturing Packaging 98

pharmaphorum

JUNE 11, 2021

Ocugen is the first company to be affected by the FDA’s recent decision to raise the bar on emergency use authorisations for COVID-19 medicines, and will have to file for full approval of its vaccine candidate. Bharat has also reported data suggesting the shot is effective against the beta (B.1.351) 1.351) variant.

Vaccination 83

Vaccination Vaccine Licensing Licensing 83

Drug Discovery World

MARCH 29, 2023

Key proposals Approved drugs must launch in all EU countries within two years Politico described this as a measure to ensure a level playing field. Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

pharmaphorum

NOVEMBER 30, 2022

The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine? The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas.

Life Science 98

Life Science Pharma Companies Sales Marketing 98

pharmaphorum

DECEMBER 21, 2020

Compared with many of the established names in pharma these companies are young upstarts but they have managed to achieve what other big names in the industry have failed to do and harness the power of mRNA to make medicine. I was intrigued by the personalities of the founders.

Vaccination 112

Vaccination Vaccine Doctors Doctor 112

Fossil Remedies

APRIL 26, 2022

PCD Pharma Business Plan. In a pharmaceutical business, you need a link between the pharma marketing company and the end-user, i.e., doctors, pharmacists, or others who can prescribe the medicine. This connecting link is the PCD Pharma Business. The Drug License Number and GST Number are these two documents.

Doctors 59

Doctors Doctor Marketing Production 59

pharmaphorum

MAY 27, 2022

This is the second in a two-part series examining how pharma can embrace the DEI agenda to create more effective medicines through more representative clinical trials. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials. What comes next? About the interviewees.

Clinical Trials 80

Clinical Trials Clinical Trials Trials Packaging 80

Delveinsight

AUGUST 2, 2020

Helsinn Group , a Swiss pharma player, is evaluating Anamorelin, an orally active selective ghrelin receptor agonist against Cancer cachexia, The company is conducting Phase III trial to test the efficacy and safety of anamorelin for the treatment of weight loss and anorexia in patients with advanced NSCLC with cachexia.

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

DECEMBER 21, 2020

It’s the first major partnership for Janux, which was set up in 2017, and could be the last to be organised by Merck’s R&D head Roger Perlmutter who is retiring from the big pharma company at the end of the year. billion alliance with Taiho and Astex for cancer antibodies, including a KRAS drug, and a $4.2

Immune Response 59

Immune Response Sales Antibody Pharma Companies 59

pharmaphorum

APRIL 19, 2022

RudaCure is a four-year-old biotech company based in the South Korea, focusing on ocular disease and chronic pain with a pair of potentially first-in-class drugs. The company recently raised $16.5 The company’s second drug candidate, RCI002, is focused on chronic pain. Early successes at home.

Marketing 52

Marketing Clinical Trials Clinical Trials Licensing 52

pharmaphorum

JANUARY 12, 2021

While there are RNAi products on the marketplace, with Alnylam becoming the first company to get a product approved in 2018, it is difficult to get this class of drug distributed through the brain and spinal cord. It also reflects the contribution from Khorova as the founder of the company.

RNA 95

RNA Production Development Pharma Companies 95

Pharmaceutical Technology

MARCH 31, 2023

On March 30, ViiV Healthcare and Medicines Patent Pool (MPP), announced sublicensing agreements with the pharma manufacturers Aurobindo , Cipla and Viatris to produce generic forms of the long-acting cabotegravir used as pre-exposure prophylaxis (PrEP) for HIV. This includes Apretude and the two oral drugs— Descovy and Truvada.

Medicine 130

Medicine Manufacturing Pharma Companies Licensing 130

pharmaphorum

MAY 14, 2021

Read below for a preview: One of the earliest and most pronounced impacts of the UK’s vote to leave the European Union was the loss of the European Medicines Agency (EMA). This leaves the UK’s drug pricing watchdog, the National Institute for Health and Care Excellence (NICE), in an uncertain position. appeared first on.

Marketing 59

Marketing Regulation Medicine Life Science 59

Delveinsight

DECEMBER 15, 2020

Gannex received US FDA fast track designation for its NASH drug, ASC42 an FXR Agonist. Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). Sold under the name Jakafi, it is FDA-approved for the treatment of polycythemia vera (PV) in adults.

Vaccination 54

Vaccination Vaccine Gene Therapy Gene 54

XTalks

DECEMBER 29, 2022

For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving gene therapies. As of December 16, 2022, there are seven US Food and Drug Administration (FDA) approved gene therapies.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

pharmaphorum

AUGUST 25, 2021

Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute Remdesivir. We went back to what we do best … we engaged our network of companies.

Marketing 52

Marketing Licensing Licensing Manufacturing 52